Literature DB >> 15668350

An underrecognized challenge in evaluating postmarketing drug safety.

Dan M Roden.   

Abstract

Mesh：

Year:  2005        PMID： 15668350     DOI： 10.1161/01.CIR.0000154578.45378.8C

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

Review 1.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

Review 3.  Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives.

Authors:  Saagar Mahida; Andrew J Hogarth; Campbell Cowan; Muzahir H Tayebjee; Lee N Graham; Christopher B Pepper
Journal:  J Interv Card Electrophysiol       Date:  2013-03-21       Impact factor: 1.900

4.  Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.

Authors:  Bradley D Freeman; David J Dixon; Craig M Coopersmith; Barbara A Zehnbauer; Timothy G Buchman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-10       Impact factor: 2.890

Review 5.  Cellular basis of drug-induced torsades de pointes.

Authors:  D M Roden
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

6.  Observational therapeutics: Scope, challenges, and organization.

Authors:  Rama Vaidya
Journal:  J Ayurveda Integr Med       Date:  2011-10

7.  A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.

Authors:  Luca Sala; Zhiyi Yu; Dorien Ward-van Oostwaard; Jacobus Pd van Veldhoven; Alessandra Moretti; Karl-Ludwig Laugwitz; Christine L Mummery; Adriaan P IJzerman; Milena Bellin
Journal:  EMBO Mol Med       Date:  2016-09-01       Impact factor: 12.137
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.